Bayer

MediaBayer starts Phase IIa study for treatment of patients with Alport Syndrome

04 Dec 2025

Data from Pediatric Study for Bayer's Investigational MRI Contrast Agent presented at RSNA 2025

04 Dec 2025

Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia

03 Dec 2025

Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention

23 Nov 2025

U.S. FDA grants accelerated approval to Bayer’s HYRNUO™ (sevabertinib) for patients with previously treated advanced HER2-mutant non-small cell lung cancer

20 Nov 2025

Lynkuet™ (elinzanetant) approved in the EU for the treatment of moderate to severe vasomotor symptoms associated with menopause or endocrine therapy for breast cancer

19 Nov 2025

Bayer AG Third Quarter 2025 Results and Media Update

12 Nov 2025

Bayer confirms 2025 Group outlook, progresses on strategic priorities

12 Nov 2025

Bayer attends the climate conference in the rainforest

10 Nov 2025

Dr. Judith Hartmann to become new Chief Financial Officer of Bayer AG

07 Nov 2025

View details about the software product Informachine News Trackers